ReviewFrontiers in neurology2018
Eye Movement Abnormalities in Multiple Sclerosis: Pathogenesis, Modeling, and Treatment.
Review in Frontiers in neurology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02391961 (Study and Treatment of Visual Dysfunction and Motor Fatigue in Multiple Sclerosis), which is not on this map. Cited by 52 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Study and Treatment of Visual Dysfunction and Motor Fatigue in Multiple Sclerosis
Who cites it
52 citing papers in PubMed, 2 syntheses or guidelines pooled it, 86 citations in OpenAlex.
- Effectiveness of vestibular rehabilitation in patients with multiple sclerosis: a systematic review and meta-analysis of randomized controlled trials.Journal of neurology · 2026Pooled it
- Recent advances (2022-2024) in eye-tracking for Parkinson's disease: a promising tool for diagnosing and monitoring symptoms.Frontiers in aging neuroscience · 2025Pooled it
- Portable eye-tracking as a reliable assessment of oculomotor, cognitive and reaction time function: Normative data for 18-45 year old.PloS one · 2021Trial
- Vertical saccadic slowing is associated with fatigue in multiple sclerosis.Fatigue : biomedicine, health & behavior · 2026Article
- Digital measurement of ocular microtremor in Parkinson's Disease: Analytical and clinical validation.PLOS digital health · 2026Article
- Baseline Oculomotor Parameters Are Prospectively Associated with Cognitive Processing Speed at 6-Year Follow-Up in Multiple Sclerosis: An Exploratory Cohort Study.Journal of clinical medicine · 2026Article
- Functional head impulse testing for detection and quantification of vestibular dysfunction in multiple sclerosis.Journal of neurology · 2026Article
- Eye tracking as a digital biomarker in neurodegenerative diseases.Journal of neurology · 2026Review
- Quantitative Analysis of Smooth Pursuit and Saccadic Eye Movements in Multiple Sclerosis.Neurology international · 2026Article
- Positional nystagmus in multiple sclerosis: a cross-sectional case-control study.BMC neurology · 2026Observational
- Visual impairment in multiple sclerosis involving post-geniculate gray and white matter: above and beyond.Frontiers in neurology · 2026Review
- Advances in ocular motor and pupil biomarkers for neurological disorders.Brain communications · 2026Review
- Current status and future prospects of brain-computer interfaces in the field of neurological disease rehabilitation.Frontiers in rehabilitation sciences · 2026Review
- Mechanisms of VOR Suppression in Brainstem Pathology: Insights from the Absence of Anti-Compensatory Saccades Despite Normal VOR Gain.Audiology research · 2025Article
- Acute Vertigo, Dizziness and Imbalance in the Emergency Department-Beyond Stroke and Acute Unilateral Vestibulopathy-A Narrative Review.Brain sciences · 2025Review
- Developmental Eye Movement (DEM) Test in Adults: Age-Related Changes and Italian Normative Data.Vision (Basel, Switzerland) · 2025Article
- Eye-Tracking Metrics as a Digital Biomarker for Neurocognitive Disorders in Multiple Sclerosis: A Scoping Review.Brain sciences · 2025Review
- Oculomotor indicators of cognitive performance are modulated by neurodegeneration.Frontiers in neurology · 2025Article
- Twenty years of natalizumab in multiple sclerosis: lessons learned and future outlook.Therapeutic advances in neurological disorders · 2025Review
- Construction of a prediction model for Alzheimer's disease using an AI-driven eye-tracking task on mobile devices.Aging clinical and experimental research · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 3 institutions in 2 countries.
Funding
Abstract
Multiple sclerosis (MS) commonly causes eye movement abnormalities that may have a significant impact on patients' disability. Inflammatory demyelinating lesions, especially occurring in the posterior fossa, result in a wide range of disorders, spanning from acquired pendular nystagmus (APN) to internuclear ophthalmoplegia (INO), among the most common. As the control of eye movements is well understood in terms of anatomical substrate and underlying physiological network, studying ocular motor abnormalities in MS provides a unique opportunity to gain insights into mechanisms of disease. Quantitative measurement and modeling of eye movement disorders, such as INO, may lead to a better understanding of common symptoms encountered in MS, such as Uhthoff's phenomenon and fatigue. In turn, the pathophysiology of a range of eye movement abnormalities, such as APN, has been clarified based on correlation of experimental model with lesion localization by neuroimaging in MS. Eye movement disorders have the potential of being utilized as structural and functional biomarkers of early cognitive deficit, and possibly help in assessing disease status and progression, and to serve as platform and functional outcome to test novel therapeutic agents for MS. Knowledge of neuropharmacology applied to eye movement dysfunction has guided testing and use of a number of pharmacological agents to treat some eye movement disorders found in MS, such as APN and other forms of central nystagmus.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.